EE687 The Budget Impact and Time Savings of Introducing Subcutaneously Administered Nivolumab and Hyaluronidase (NIVO SC) to Patients Receiving Intravenously Administered Nivolumab (NIVO IV) Across Indications in Canada
Abstract
Authors
Dimitrios Tomaras Victor Genestier Karishma Shelley